DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients

Information source: Brigham and Women's Hospital
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Heart Failure

Intervention: Acetazolamide (Drug); Placebo (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Atul Malhotra, MD

Official(s) and/or principal investigator(s):
Atul Malhotra, MD, Principal Investigator, Affiliation: Brigham and Women's Hospital


The ultimate goal is to improve our understanding of the pathophysiology and resistance to effective treatment of sleep disordered breathing in patients with heart failure, with a focus on selecting patients that will benefit specifically from acetazolamide treatment.

The study addresses three primary hypotheses: 1) Acetazolamide treatment will reduce the apnea-hypopnea index and improve markers of heart-failure severity in heart-failure patients with sleep apnea. 2) Acetazolamide will provide the greatest improvement in patients with the least severe ventilatory control instability (lowest loop gain). 3) Acetazolamide will act primarily via stabilizing ventilatory control (reducing loop gain), rather than via improvement to upper airway anatomy, pulmonary congestion, and cardiac function.

Clinical Details

Official title: Physiological Study to Predict Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Primary outcome: The severity of sleep disordered breathing (apnea-hypopnea index, AHI)

Secondary outcome:

Ventilatory stability, i.e. loop gain, ventilatory sensitivity to carbon dioxide

Sympathetic activity (urinary norepinephrine)

Cardiac function, assessed by echocardiography

Closing volume

Brain natriuretic peptide (BNP and NT-proBNP)

Subjective sleep quality, breathlessness, fatigue (Quality of life)

Troponin I


Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria:

- LVEF<50%

- Age 18-80

Exclusion Criteria:

- severe obstructive respiratory disease

- unstable heart failure status

- recent use of positive airway pressure therapy

- current use of medications known to affect ventilation

- severe kidney disease

- hemoglobin <9. 5g/dl (moderate-severe anemia)

Locations and Contacts

Brigham and Women's Hospital, Boston, Massachusetts 02115, United States; Recruiting
Scott A Sands, PhD, Email: sasands@partners.org
Additional Information

Starting date: August 2011
Last updated: October 19, 2012

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014